Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis

被引:1
|
作者
van Husen, Georg [1 ]
Virdone, Saverio [2 ]
Pieper, Karen [2 ]
Kayani, Gloria [2 ]
Fox, Keith A. A. [3 ]
机构
[1] Tenac Io, Oberwallstr 6, D-10117 Berlin, Germany
[2] Thrombosis Res Inst, Dept Stat, London, England
[3] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
来源
关键词
Atrial fibrillation; Universal Clinician Device; Management guidelines; Diabetes; Personalized medicine; Risk prediction; CARDIOVASCULAR OUTCOMES; WARFARIN; STROKE; EMPAGLIFLOZIN; MORTALITY;
D O I
10.1093/ehjdh/ztac011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Atrial fibrillation (AF) management guidelines advise using risk tools to optimize AF treatment. This study aims to develop a dynamic and clinically applicable digital device to assess stroke and bleeding risk, and to facilitate outcome improvements in AF patients. The device will provide tailored treatment recommendations according to easily attainable individual patient data. Methods and Results This Universal Clinician Device (UCD) was created using the GARFIELD-AF registry using a split sample approach. The GARFIELD-AF risk tool was adapted with two modifications. First, predictors with >= 1000 missing data points were separated, allowing expected risks estimation. Second, recommendations for modifiable risk factors and associated 2-year outcome estimates were incorporated. Outcomes of interest were all-cause mortality, non-haemorrhagic stroke/systemic embolism (SE), and major bleeding. All patients were randomized to a derivation (n=34853) and validation cohort (n=17165). In the derivation cohort, predictors were identified using least absolute shrinkage and selection operator regression. Cox models were fitted with the selected parameters. The UCD demonstrated superior predictive power compared with CHA(2)DS(2)VASc for all-cause mortality [0.75(0.75-0.76) vs. 0.71(0.70-0.72)] and non-haemorrhagic stroke/SE [0.68(0.66-0.70) vs. 0.65(0.63-0.67)], and with HAS-BLED for major bleeding [0.69(0.67-0.71) vs. 0.64(0.62-0.65)]. Universal Clinician Device recommendations reduced all-cause mortality (8.45-5.42%) and non-haemorrhagic stroke/SE (2.58-1.50%). Patients with concomitant diabetes and chronic kidney disease benefitted further, reducing mortality risk from 13.15% to 8.67%. One-third of patients with a CHA(2)DS(2)VASc score of >1 had the lowest risk of stroke. Conclusion The UCD simultaneously predicts mortality, stroke, and bleeding risk in patients using easily attainable individual clinical data and guideline-based optimized treatment plans. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362
引用
收藏
页码:181 / 194
页数:14
相关论文
共 50 条
  • [1] Improving risk prediction for death, stroke and bleeding in Asian patients with atrial fibrillation
    Krittayaphong, Rungroj
    Kanjanarutjawiwat, Wiwat
    Wisaratapong, Treechada
    Lip, Gregory Y. H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (02)
  • [2] Improving anticoagulation management in patients with atrial fibrillation
    Dager, Willam E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (21) : 2279 - 2280
  • [3] Quantitative Risk-Benefit Analysis of Oral Anticoagulants in Patients with Atrial Fibrillation
    Hsu, Jason C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 387 - 387
  • [4] A clinician viewpoint on the 2024 European guidelines on the management of patients with atrial fibrillation
    Fauchier, Laurent
    Deharo, Jean Claude
    Sacher, Frederic
    Cohen, Ariel
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2025, 118 (02) : 81 - 84
  • [5] Targeting patients with atrial fibrillation and improving their anticoagulation management
    Kamath, S
    Lip, GYH
    CLINICAL CARDIOLOGY, 2001, 24 (05) : 355 - 357
  • [7] Incremental Benefit Of Echocardiography In The Assessment Of Thromboembolic Risk In Patients With Atrial Fibrillation
    Hong, L.
    Croft, L. B.
    Goldman, M. E.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S175 - S175
  • [8] Risk assessment and management of atrial fibrillation patients with left atrial thrombus
    Miyazawa, Kazuo
    Lip, Gregory Y. H.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2019, 42 (01): : 1 - 3
  • [9] Balancing risk and benefit in patients with atrial fibrillation: the GARFIELD-AF risk score
    Fox, K.
    Virdone, S.
    Pieper, K.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3577 - 3577
  • [10] New biomarkers from multiomics approaches: improving risk prediction of atrial fibrillation
    Kornej, Jelena
    Hanger, Vanessa A.
    Trinquart, Ludovic
    Ko, Darae
    Preis, Sarah R.
    Benjamin, Emelia J.
    Lin, Honghuang
    CARDIOVASCULAR RESEARCH, 2021, 117 (07) : 1632 - 1644